{"id":"W2587089540","doi":"10.1016/s0923-7534(21)00598-6","title":"440O Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm +) NSCLC: overall survival (OS) sdata from LUX-Lung 7 (LL7)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency; Ottawa Hospital; McGill University","funders":"Eisai; Ariad Pharmaceuticals; Gilead Sciences; Chugai Pharmaceutical; Amgen; Pfizer; Genentech; AstraZeneca; Allergan; Eli Lilly and Company","keywords":"Medicine; Afatinib; Gefitinib; Internal medicine; Clinical endpoint; Lung cancer; Oncology; Gastroenterology; Clinical trial; Cancer; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006539474,0.0003200815,0.0009407686,0.0002453007,0.0001845006,0.0007017443,0.0003263754,0.0006386854,0.003112322],"category_scores_gemma":[0.0007046208,0.0001424876,0.00125854,0.0002715243,0.0003337567,0.0007948047,0.0003201902,0.001207916,0.0005379512],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005966455,"about_ca_system_score_gemma":0.0006576787,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001288015,"about_ca_topic_score_gemma":0.004254626,"domain_scores_codex":[0.9996421,0.0001102038,0.00002888118,0.00006462352,0.00003085486,0.0001232914],"domain_scores_gemma":[0.9996904,0.00007744038,0.00005304785,0.0000152499,0.0000170279,0.0001468691],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7672805,0.004507321,0.06874476,0.0005660847,0.002146635,0.00032054,0.0001794346,0.001983808,0.01187608,0.0004377579,0.006059598,0.1358975],"study_design_scores_gemma":[0.1953201,0.4015832,0.3696103,0.0002782187,0.005497645,0.001398324,0.0007944649,0.005588035,0.007072141,0.001280597,0.01143426,0.0001426898],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9947616,0.002367007,0.00006276054,0.0003594713,0.0001215607,0.00003904595,0.0004722769,0.00001672468,0.001799572],"genre_scores_gemma":[0.9971622,0.0006984724,0.00009394541,0.0003139249,0.0001024986,0.00003160015,0.0008581849,0.00000433559,0.0007348573],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003112322,"threshold_uncertainty_score":0.01041174,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03230020250565641,"score_gpt":0.3771746745983067,"score_spread":0.3448744720926503,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}